US Patent

US9682075 — Tamper-resistant pharmaceutical compositions of opioids and other drugs

Method of Use · Assigned to Collegium Pharmaceutical Inc · Expires 2030-12-10 · 5y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects tamper-resistant pharmaceutical compositions that slow the release of a drug, such as an opioid, even if the formulation is compromised.

USPTO Abstract

Tamper-resistance pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1556 — OxyContin
U-1556 — OxyContin
U-1556 — OxyContin
U-1556 — OxyContin
U-1556 — OxyContin

Patent Metadata

Patent number
US9682075
Jurisdiction
US
Classification
Method of Use
Expires
2030-12-10
Drug substance claim
No
Drug product claim
Yes
Assignee
Collegium Pharmaceutical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.